Completed PHASE1 INTERVENTIONAL 3-arm NCT02174510

A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd.

Interventions 20mg lurasidone 40mg lurasidone 80mg lurasidone placebo

Updated 9 times since 2017 Last updated: Jan 9, 2019 Started: Mar 31, 2014 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02174510, this PHASE1 trial focuses on Schizophrenia and remains completed. Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd., it has been updated 9 times since 2014, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Oct 2022 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jan 2021 — Oct 2022 [monthly]

Completed PHASE1
Feb 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Feb 2019 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sumitomo Pharma (Suzhou) Co., Ltd.
Xuhui Central Hospital, Shanghai

Data source: Sumitomo Pharma (Suzhou) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China